Project Deep Dive

Summary:

Lower grade glioma (LGG) and leiomyosarcoma (LMS) are rare cancers with poor survival rates. A typical treatment option includes radiation therapy, but these cancers are very likely to return after radiation therapy. The mechanisms behind radiation resistance in these rare cancers are not well understood, which causes barriers in effectively treating these diseases. Researchers from Count Me In and OPTIMUM will collaborate to understand how cancer cells adapt and create resistance to radiation therapy.

Researchers will utilize a technique called spatial proteomics on specimens from patients to understand how cells interact and how their environments evolve in cases of untreated recurrence and under radiation treatment for recurrent cases. Additionally, they will utilize another technique called spatial transcriptomics on specimens from patients with LGG and LMS to understand how cells are organized and how they respond to radiation therapy.

This project is innovative as it combines state-of-the-art technologies with real-world patient data, allowing researchers to explore the complex relationship between genetics and treatment response. Ultimately, the aim is to find new strategies to overcome radiation therapy resistance and improve outcomes by offering personalized treatment options for patients battling LGG and LMS.